LYTIR

Company · LCTX

Lineage Cell Therapeutics, Inc.

Nasdaq's symbol directory lists LCTX on NYSE American as “Lineage Cell Therapeutics, Inc. Common Stock”.

In the 12 months to Nov 19, 2026: insiders bought on 3 occasions ($74K); 1 company report (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Brian M. Culley, President and CEO bought on 1 day latest Nov 16, 2026 bought $37K
  2. Deborah J. Andrews bought on 1 day latest Nov 16, 2026 bought $20K
  3. Jill A. Howe, Chief Financial Officer bought on 1 day latest Nov 16, 2026 bought $17K
Every trade (3)
  1. BUYBrian M. Culley, President and CEO bought Nov 16, 2026 40,500 shares filing $37K
  2. BUYDeborah J. Andrews bought Nov 16, 2026 25,000 shares filing $20K
  3. BUYJill A. Howe, Chief Financial Officer bought Nov 16, 2026 20,000 shares filing $17K

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Entry into a material definitive agreement; Completion of acquisition or disposition of assets; Results of operations and financial condition; Unregistered sales of equity securities; Regulation FD disclosure filing Nov 12, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.